Results 211 to 220 of about 1,221,083 (383)

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen   +14 more
wiley   +1 more source

Transition from psoriasis to psoriatic arthritis is characterized by distinct alterations in peripheral blood Tc17, Th17 and CD4+ TEM cells

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cellular mechanisms driving transition from psoriasis to psoriatic arthritis have remained largely elusive. Thus, we investigated changes within the peripheral blood T cell compartment associated with the transition phase. Methods In an observational study, 116 patients were examined and categorized into subgroups including psoriasis with at ...
Hanna Graßhoff   +19 more
wiley   +1 more source

Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN‐DU study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of juvenile idiopathic arthritis (JIA) patients. Methods The international UCAN CAN‐DU study prospectively enrolls JIA patients across Canada and the Netherlands.
Jelleke B. de Jonge   +102 more
wiley   +1 more source

Clinical Images: Methotrexate‐induced melanonychia

open access: yes
Arthritis &Rheumatology, EarlyView.
Yoshinori Taniguchi, Hirotaka Yamamoto
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

open access: yesArthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Home - About - Disclaimer - Privacy